2011

Welcome to Pharma Social Marketers Anonymous (PSMA)! You are among friends. Soon, you will take important steps on the path to overcoming your fear of social media. The first step is to admit you are powerless over social media and that your online life has become unmanageable. Are you ready to take ALL 12 steps toward recovery?

David Epstein, head of Novartis Pharmaceuticals, said eighty percent of his company's sales reps will give up their PCs for iPads in 2012. Will they do it?

If you're thinking of developing a mobile application (app) for patients or physicians, you need to consider the myriad platforms -- hardware plus software combinations -- that are out there and determine which platform is best suited for your intended audience. Your choice of platform will impact your app's performance, maintenance, and security, which in turn will make or break the success of the app.

How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?

Pharma Marketing News is the monthly e-newsletter of the Pharma Marketing Network (www.pharma-mkting.com). It is packed with facts, opinions, and case studies based upon interviews with experts in the field of pharmaceutical marketing. Highlights of presentations from industry conferences, contact lists for experts consulted, and links to references help susbcribers keep up to date on best practices and network with their peers.

Are we witnessing an exodus of social media

Opening the Door to FDA-Compliant Branded Tweets: Deck.ly has enormous potential for pharmaceutical marketers who have been chaffing at the bit to post meaningful branded messages via Twitter but who have been stymied by lack of guidance from FDA regarding how to provide fair balance within the 140-character limit of Twitter.

A conversation with Monique Levy, VP Research at Manhattan Research, about the changing pharma eDetailing landscape. Ms. Levy discusses how the online pharma promotion landscape has changed, and which types of programs garner the largest audience as well as how the rep relationship is evolving and the role of new technologies such as tablets.

Why do pharma companies bother developing drugs for for a disorder affecting fewer than 200,000 people? Willie Sutton's ghost may have the answer.

Welcome to Volume 10, Issue #10 (8 JUNE 2011) of Pharma Marketing News.